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Pseudohypoparathyroidism type Ia (PHP Ia) is deﬁned as a series of disorders characterized by multihormone resistance in end-
organs and Albright hereditary osteodystrophy (AHO) phenotype. PHP Ia is caused by heterozygous inactivating mutations
in GNAS, which encodes the stimulatory G-protein alpha subunit (Gsa). A patient with typical clinical manifestations of
pseudohypoparathyroidism (PHP) (round face, short stature, centripetal obesity, brachydactyly, and multi-hormone resistance:
parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), and gonadotropins) presented at our center. The sequence of
the GNAS gene from the patient and her families revealed a novel missense mutation (Y318H) in the proband and her mother. An
in vitro Gsa functional study showed that Gsa function was signiﬁcantly impaired. These results stress the importance of GNAS
gene investigation.
1.Introduction
PHP Ia and pseudo-pseudohypoparathyroidism (PPHP) are
disorders caused by heterozygous inactivating mutations
in GNAS, which encodes Gsa, and usually coexist in
the same family [1, 2]. Paternal transmission of GNAS
mutations only lead to the AHO phenotype, which is
characterized by a round face, short stature, centripetal
obesity,brachydactyly,Subcutaneous(sc)ossiﬁcations,men-
tal deﬁcits, or developmental delay, and is termed PPHP.
Maternal transmission leads to AHO plus hypocalcemia,
hyperphosphatemia, and multi-hormone resistance, such as
toPTH,TSH,gonadotropins,andgrowthhormonereleasing
hormone (GHRH), and is termed PHP Ia [1, 3–6].
The GNAS gene is located on chromosome 20q13.11 and
consists of 13 exons and 12 introns [1]. GNAS mutations
have been found throughout the coding sequence of the
gene [4, 7], and about 35% of all mutations described are
within exon 7. Many authors have demonstrated the tissue-
speciﬁc imprinting nature of Gsa [8]. In PHP Ia patients,
GNAS is biallelically expressed in most tissues, in which
Gsa activity was reduced by approximately 50% because
of a reduction of Gsa mRNA and protein expression [9].
While in few other tissues such as renal proximal tubules, the
thyroid, the gonads, and the pituitary, GNAS is maternally
expressed because of the suppression (imprinting) of the
paternal allele [4, 10]. This might explain why the multi-
hormone resistance in PHPIA patients primarily involves
four hormones: PTH, TSH, gonadotropins, and GHRH
[4, 11], all of which stimulate Gs-coupled pathways in their
target tissues.
Here we reported a PHP family and a novel missense
mutation (c.952 T>C, Y318H) in the GNAS gene of this
family.
2. Patients Presentation
2.1.Cases. Thefemaleprobandwastheproductofanormal-
term delivery and was the second child of her family. Her2 International Journal of Endocrinology
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Figure 1: (a) The proband appeared short, obese, and face round. (b) The proband’s hands. (c) The proband’s feet. (d) Feet of the proband’s
mother. (e) An X-ray of patient’s right hand showing that her metacarpals and phalanges are generally shortened. The both ends of the
twice-ﬁfth metacarpals are enlarged. The ﬁrst distal phalanx, twice-ﬁfth middle phalanges and twice-ﬁfth distal phalanges are thickened. (f)
The X-ray of the patient’s right foot showing that her metatarsus and phalanges are generally shortened, especially the ﬁrst metatarsus and
phalanx. The distal ends of the ﬁrst metatarsus, ﬁrst phalanx, and twice-ﬁfth phalanges are enlarged. The proximal ends of the ﬁrst phalanx
and twice-ﬁfth phalanges are widened. (g) The feet of the patient’s mother looked normal; however, an X-ray of her right foot showed that
she had a similar, but less severe, phenotype to her daughter.
birth weight and length were in the normal range, except for
abnormal weight gain and short stature, no further atypical
signs were observed in childhood. She underwent her ﬁrst
menstruation at the age of 15, but the menstrual cycle was
about 6 months and was accompanied by oligomenorrhea.
In addition, her breast remained undeveloped. She attended
ourhospitalforbreastdevelopmentretardationandirregular
menstruation at the age of 22. At this time, she showed
features of AHO: round face, short stature, and overweight
(65kg, height 142cm), resulting in an abnormal body
mass index (32.25kg/m2)( Figure 1(a)). In addition, she
also showed brachymetacarpia (Figures 1(b) and 1(e)) and
brachymetatarsia (Figures 1(c) and 1(f)).
Her mother showed features of slight AHO, such as
a round face, short stature, and slight brachymetatarsia
(Figure 1(g)). Her weight was 46kg, and her height was
148cm, resulting in a normal body mass index (21kg/m2).
Biochemical details of the patient revealed apparent
elevated PTH, serum calcium in the midnormal range,
and normal serum phosphate. She also displayed multi-
hormone resistance, characterized by elevated plasma TSH
and decreased plasma Estradiol (E2). The growth hormone
Table 1: Blood biochemical and hormonal analysis.
Ib I Ib N o r m a lv a l u e
Serum Calcium 2.56 2.39 2.0–2.8mmol/L
Serum Phosphate 1.1 1.51 0.8–1.6mmol/L
Plasma PTH 27.52 152.4 15–65pg/mL
Plasma GH 4.216 4.763 <5ng/mL
Plasma TSH 3.73 14.56 0.27–4.2uIU/mL
Plasma Free T3 3.53 3.18 3.1–6.8pmol/L
Plasma Free T4 18.23 8.47 12–22pmol/L
Plasma LH Normal 6.67 2.4–12.6mIu/mL
Plasma FSH Normal 11.34 3.5–12.5mIu/mL
Plasma Estradiol Normal 23.34 24.5–195pg/mL
Plasma INS 13.34 15.29 2.6–24.9uIU/mL
Values in italics represent means outside the reference range; I b represented
patient’s mother; II b represented the patient.
(GH) level and islet function test results were normal. The
patient’smotherdidnotshowanysignofhormoneresistance
(Table 1).International Journal of Endocrinology 3
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Figure 2: (a) Sequencing analysis of exon 11 in patient II b. The ﬁgure shows that the missense mutation at codon 318 results in a Tyr to
His substitution. The same mutation was found in the proband’s mother, who is aﬀected by PPHP. (b) Gsa conservation analysis with CLC
free, the result shows that Gsa codon 318 is in the highly conserved region. (c) The tertiary structure of Gsa, α4-β6l o o pw a ss h o w ni nr e d ,
and Tyr-318 residue was the green point indicated by green arrow. (d) A cAMP assay was used to assess the Gsa function of GNAS WT and
GNAS MT, with or without stimulation with PTH 1–34 (10−8 M) in OK cells. ∗P<0.05; ∗∗P<0.01; ∗∗∗P<0.001 (compared with control).
###P<0.001 (compared with GNAS WT).
The parents gave informed consent to further investiga-
tions of all family members.
2.2. Sequencing Analysis. Direct sequencing of the ampliﬁed
GNAS genomic DNA fragments revealed a heterozygous
missense mutation within exon 11 (c.952 T>C) (Figure 2(a))
in the proband. The T>C transversion results in a Tyr to
His substitution at codon 318 (Y318H, NP 000507.1). To the
best of our knowledge, this is a novel mutation in GNAS
(http://www.HGMD.cf.ac.uk/ac/index.php). This mutation
was also found in patient’s mother, who was aﬀected with
PPHP. No mutation was detected in other family members
(Figure 3) and 50 healthy individuals. And the mutation has
been conﬁrmed on second PCR products.
2.3. In Vitro Gsa Biological Activity Analysis. Functional Gsa
can stimulate adenylyl cyclase, which can catalyze the syn-
thesis of cAMP from ATP within cells [4]. To determine
whether this is a loss of function mutation, OK cells were
transfectedwithpEGFP-N1(asacontrol),pEGFP-N1-GNAS
WT (wild type), and pEGFP-N1-GNAS MT (mutant type),
respectively, and stimulated with PTH 1-34. OK cells were
chosen because of their endogenous expression of PTH
receptor type 1 [12]. The results showed that compared4 International Journal of Endocrinology
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Figure 3: Family tree of the patient.
with GNAS WT, though the GNAS MT can still enhance
cAMP accumulation in OK cells (GNAS WT compared with
control: 26.32 ± 1.29nM versus 3.69 ± 1.84nM, P<0.01
a n dG N A SM Tc o m p a r e dw i t hc o n t r o l :5 .26 ± 1.36nM
versus 3.69 ± 1.84nM, P<0.05. Figure 2(d)), GNAS MT’s
function was signiﬁcantly impaired, either when treated
with PTH or untreated (GNAS MT compared with GNAS
WT: untreated with PTH 5.26 ± 1.36nM Versus 26.32 ±
1.29nM, P<0.001; treated with PTH 13.96 ± 1.79nM
versus 68.92 ± 1.79nM, P<0.001. Figure 2(d))[ 12].
The identiﬁcation of a GNAS mutation and reduced Gsa
activity conﬁrmed the presumptive diagnosis of PHPIa and
PPHP.
3. Discussion
By direct sequencing analysis of proband’s GNAS gene we
discovered a heterozygous missense mutation within exon 11
(c.952 T>C), though there were many mutations that have
been reported before (http://www.HGMD.cf.ac.uk/ac/index
.php). This mutation is novel, thus expanded the spectrum
of GNAS mutation associated with PHP and PPHP. Besides
it is the ﬁrst missense mutation of GNAS detected in Chinese
Han PHP family. This mutation in exon 11 results in a Tyr to
His substitution at codon 318 (Y318H, NP 000507.1). Gsa
codon 318 is in the highly conserved region (Figure 2(b)),
which is considered to have more important biological
signiﬁcance. Measurement of cAMP in wild-type and Y318H
mutant GNAS transfected OK cells demonstrated that the
missense mutation could signiﬁcantly impair Gsa func-
tion. This was roughly consistent with previously reported
50% reductions of Gsa function in PHPIa and PPHP
[9].
GNAS has been termed one of the most complex gene
loci in the human genome [7]. Moreover, several diﬀerent
transcript variants from GNAS have been described, and two
long (Gsa-L) and two short (Gsa-S) transcript variants are
created, by diﬀerential splicing of exon 3 and/or use of two
5  splice sites of exon 4. These variants contain alternatively
spliced exon 3 and/or a CAG sequence, respectively [7, 13].
Each of these variants is capable of stimulating both
adenylate cyclase and calcium channels and can represent
the transcript for functioning proteins [14]. In addition,
thesevariantsareregardedtobefunctionallynearlyidentical.
Gsa-L and Gsa-S were also shown to be biochemically nearly
indistinguishableinamammaliancelllinethatlacksendoge-
nous Gsa [15]. Therefore, we selectively constructed a typical
longtypeofGsa(ALEXGNASL,394aa)asarepresentative.G
protein is integral component of various signaling pathways;
it consists of α and βγ subunits. Inactivated Gsa is integrated
with βγ subunits; the comparison of structure of Gsa with
that of inhibitory G-protein alpha subunit (Gia) suggested
that the βγ binging surface of Gsa is strictly conserved in
sequenceandstructuretothatofGia,exceptforthecarboxyl-
terminalhelixandtheα4-β6loop, thatmaymediatereceptor
speciﬁcity [16], as is showed in Figure (Figure 2(c)). Our
patient’s mutation in residue Tyr-318 is located within the
α4-β6 loop. Thus we speculate that the reason for this
missense mutation in our patients resulting in a partial
deﬁciency (50%) of Gsa is possibly that the exchange of Tyr
to His in Gsa aﬀected the binding of Gsa with βγ.H o w e v e r ,
the precise mechanism causing loss of function of Tyr 318
His mutant Gsa needs farther study.
GNAS has the feature of genomic imprinting [14],
transmission of GNAS mutations through the maternal
germline results in PHP Ia, whereas inheritance from the
father causes only AHO [4]. We sequenced GNAS gene
of proband and her families, but only examined mutation
(Y 318 H) in proband and her mother. Considering variation
of phenotype due to genomic imprinting [8], it is easily to
understand patient’s genotype and phenotype of PHP Ia.
One reasonable explanation for patient’s mother’s genotype
and slight AHO is that the mutation came from germ cell
oﬀered by her father, but it was impossible to validate. Over-
all, the pattern of transmission of this novel heterozygous
mutation is consistent with the general model proposed for
PHP.
4. Conclusion
AlthoughmanymutationsthatcanimpairGsafunctionhave
been identiﬁed in GNAS, the c. 952 T>C missense mutation
is novel, and it is the ﬁrst missense mutation of GNAS
detected in Chinese Han PHP family. The identiﬁcation
of this mutation contributes to the understanding of the
genotype of PHP and stressed the importance of GNAS gene
investigation in diagnosis of PHP.
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